Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
BHC - Bausch Health Companies Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.00
DETAILS
HIGH:
$8.00
LOW:
$8.00
MEDIAN:
$8.00
CONSENSUS:
$8.00
UPSIDE:
68.07%
Stock News
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Thermage ® , a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system. LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands.
Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Bausch Health Announces 2026 Annual Meeting of Shareholder Results
LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D.
Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the risk of moderate-to-advanced AMD progression with a unique B-vitamin complex.* Built on decades of leadership in AREDS-based vitamins, PreserVision AREDS3 is the mos.
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
LAVAL, QC, May 13, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on Wednesday, May 20, 2026.
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
LAVAL, QC, May 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference in Austin, Texas on Tuesday, May 19, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy cutter on the Stellaris Elite® Vision Enhancement System. “The launch of Bi-Blade+ is the latest example of our commitment to delivering meaningful innovation in Europe,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “Stellaris Elite has.
Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging
Bausch Health delivered a Q1 revenue and net profit beat, but organic growth remains weak and demand is stagnant. BHC's improved margins stem from reduced rebates and discounts, but underlying sales volumes declined, especially in key segments. The investment thesis hinges on deleveraging; if debt is reduced by 20-30%, shares could rise 15-30%, but risks remain high.
Why Bausch Health Companies Was Crawling Higher This Week
There was notable growth on both the top and bottom lines. The two metrics also topped analyst estimates.
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength
Bausch Health posts mixed Q1: EPS misses, but revenues beat estimates on strong Salix and Solta growth. Pipeline progress and the raised 2026 view add momentum.
Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript
Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript
Bausch Health (BHC) Lags Q1 Earnings Estimates
Bausch Health (BHC) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.59 per share a year ago.
Compared to Estimates, Bausch (BHC) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Bausch (BHC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment charge GAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year period Adjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32% Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2026 RESULTS Delivered twelfth consecutive quarter of year-over-year Revenue growth and Adjusted EBITDA (non-GAAP)1 growth, with 14% Reported and 9% Organic (non-GAAP)1 Revenue growth and 17% Adjusted EBITDA (non-GAAP)1 growth Generated $319 million in Adjusted Cash Flow from Operations (non-GAAP) 1 Reaffirming full-year 2026 Revenue, Adjusted EBITDA (non-GAAP)1, and Adjusted Cash Flow from Operations (non-GAAP)1 guidance LAVAL, QC, April 29, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2026 financial results and other key updates from the quarter. "Our first quarter performance marks twelve consecutive periods of year‑over‑year growth in revenue, adjusted EBITDA for Bausch Health excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization.
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmology and Therapy published a narrative review highlighting the role of certain B vitamins in reducing the risk of development and progression of AMD1, a leading cause of vision loss in Americans 50 years of age or older.2 Drawing on more than two decades of scientific research, the publication synt.
Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channels LAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced Biafine® Skin Recovery Emulsion is now offered through convenient online ordering in the United States. The well-known French skincare formula is available through select online channels.
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite® Vision Enhancement System. “Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of it.
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European commercial availability of the preloaded enVista Envy full range of vision intraocular lens (IOL), which offers excellent dysphotopsia tolerance on the widely used enVista IOL platform. “Bausch + Lomb now offers two full range of vision premium IOLs - enVista Envy and LuxLife™ to meet the evolving needs.
Price Targets
Bausch Health price target raised to $8 from $7 at Truist
$8.00
(was $7.63)
Les Sulewski
·
Truist Financial
Bausch Health initiated with an Equal Weight at Barclays
$8.00
(was $6.82)
Glen Santangelo
·
Barclays
Bausch Health price target raised to $10 from $8.50 at RBC Capital
$10.00
(was $8.06)
Douglas Miehm
·
RBC Capital
Bausch Health price target lowered to $7 from $8 at Truist
$7.00
(was $5.69)
Les Sulewski
·
Truist Financial
Bausch initiated with Market Perform on Xifaxan risk at Raymond James
$8.00
(was $7.19)
Michael Freeman
·
Raymond James
Bausch Health Companies (BHC) PT Raised to $9 at Piper Sandler
$9.00
(was $8.78)
David Amsellem
·
Piper Sandler
Bausch Health Companies (BHC) PT Lowered to $11 at RBC Capital
$11.00
(was $8.45)
Doug Miehm
·
RBC Capital
Jefferies on BHC (BHC): 'We see this as an extremely positive outcome for BHC and removes a key barrier to executing the spin'
$16.00
(was $9.28)
Glen Santangelo
·
Jefferies
Bausch Health Companies (BHC) PT Raised to $12 at RBC Capital
$12.00
(was $10.05)
Doug Miehm
·
RBC Capital
Piper Sandler Maintains Neutral on Bausch Health Companies, Lowers Price Target to $6
$6.00
(was $6.70)
Piper Sandler
RBC Capital Maintains Outperform on Bausch Health Companies, Lowers Price Target to $12
$12.00
(was $8.73)
RBC Capital
RBC Capital Maintains Outperform on Bausch Health Companies, Lowers Price Target to $17
$17.00
(was $10.45)
RBC Capital